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In memory of Rolf Huisgen.
Abstract: We have worked out a new approach to 1,3,4-trisub-
stituted -carbolines of pharmaceutical interest. As central
building blocks we used 2-acylindoles, which are readily avail-
able from indole-2-Weinreb amides. Bromination at C-3, fol-
Introduction
The -carbolines represent a large and structurally diverse class
of secondary metabolites from plants, marine invertebrates, and
microorganisms. A broad spectrum of biological activities has
been demonstrated for -carbolines, e.g. antimicrobial, anti-
parasitic, antiviral, neuropharmocological,[1a] antitumor,[1b] and
antiprotozoal[1c,1d] activities.
Previous research was mainly focused on the synthesis of
-carbolines bearing various residues at C-1, eventually in com-
bination with substituents on ring C, e.g. a methoxy group at
C-7 in harmine, a well-documented inhibitor of monoamine
oxidase A (MAO-A) and protein kinases like DYRK1A.[2] The most
common approaches to -carbolines bearing residues at C-1
(reviewed in ref.[3]) start from tryptamine or tryptophan (A), and
pyridine ring A is built up using either an aldehyde (Pictet–
Spengler reaction)[4] or a carboxylic acid (Bischler-Napieralski
reaction).[5] Fully aromatic compounds are obtained in a final
dehydrogenation step of the intermediate di- or tetrahydro--
carbolines. Alternatively, 1-substituted -carbolines are avail-
able via Pd-catalyzed cross-coupling of 1-halogenated -carbol-
ines (C),[6] reaction of 1,9-dimetalated -carboline with electro-
philes,[7] and regioselective homolytic substitution reactions.[8]
The precursors for these reactions are prepared from trypt-
amine as well. All of these approaches are primarily suitable for
the construction of -carbolines bearing various residues at
C-1, and, depending on the utilization of tryptamine precursors
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lowed by Suzuki–Miyaura cross-coupling with isoxazole-4-bor-
onates gives 2-acyl-3-isoxazolylindoles. Ring closure to the -
carbolines was accomplished by reductive ring transformation
upon catalytic hydrogenation in the presence of Cs2CO3.
bearing substituents on the benzene ring, -carbolines having
additional functional groups on ring C (Figure 1).
Figure 1. Published approaches to variously substituted -carbolines with
special focus on substituents on ring A.
The utilization of tryptamine building blocks in most of the
common approaches towards -carbolines means that intro-
duction of additional residues at C-3 and C-4 of the target -
carbolines is typically not possible. Tryptamines bearing addi-
tional residues in the side chain are available via electrophilic
substitution of indoles at C-3 with appropriately substituted
nitroalkenes in several steps.[3] For an application in the synthe-
sis of the alkaloid (S)-brevicolline, see ref.[9] Tryptamine deriva-
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tives obtained by functionalization of gramine with α-(alkylide-
neamino)nitriles furnished 1,3-disubstituted -carbolines.[10] A
convenient alternative approach was introduced by Larock[11]
with the Pd-catalyzed cyclization of 3-alkynyl-2-formylindoles
via the corresponding tert-butylimines (B, R1 = H) to give 3-
substituted -carbolines. Rossi[12] published a variation starting
from 2-acylindoles that provides 1,3-disubstituted -carbolines
in a similar manner. Larock's methodology was extended to the
synthesis of 3,4-disubstituted -carbolines by reacting internal
alkynes with tert-butylimines of 3-iodoindole-2-carbaldehydes
(D), but typically mixtures of regioisomers were obtained.[13]
Jiao demonstrated that this iminoannulation can be accom-
plished even without the 3-iodo substituent on the indole-2-
carbaldimine, if oxygen was used as an oxidant.[14] However, all
of these methods for construction of ring A starting from alk-
ynes require protection of the indole nitrogen, and only few
examples for readily removable protective groups (sulfonyl,
MOM) have been presented by the authors. For some additional
approaches to ring A-substituted -carbolines see ref.[15–18] In
the past, we developed a number of -carbolines as inhibitors
of protein kinases (CLK1,[19] DYRK1A,[2,19a] PIM1[19a,20]), and de-
tected pronounced effects of the substitution patterns at both
ring C, the indole nitrogen, and C-1 on the biological activities.
However, in the group of fully aromatic -carbolines we worked
on until now, substituents at C-3 and C-4 of ring A could not
be investigated, since typically our building blocks were pre-
pared from precursors that do not allow functionalization at
C-3/C-4. In our attempt to establish broader structure-activity
relationship (SAR) analysis of bioactive -carbolines, we saw a
need for working out novel methodologies for the synthesis of
-carbolines, which still can be modified freely at ring C (by
selecting commercially available starting materials with mani-
fold substitution patterns) and at C-1, but in addition the new
protocol should enable us to introduce residues at C-3 and
C-4 in a predictable manner and without formation of isomeric
products.
As the chemistry of 1,3,4-trisubstituted -carbolines is rather
underexplored, we worked out an unprecedented approach to
this chemotype. For the central step in the construction of the
pyridine ring (ring A) we selected a formal cyclocondensation
of an 1,5-diketone (or an equivalent E thereof ) under incorpora-
tion of ammonia (Figure 2). Comparable cyclocondensations
have been published before by others[21] and by us (using an
enol ether as carbonyl equivalent).[22a] As building block for
rings B+C as well as C-1 of ring A and the substituent R1 located
there, we selected 2-acylindoles (G/H). These are readily avail-
able from indole-2-Weinreb amides,[22] which in turn can, with
a broad variety of substituents at the benzene ring, be prepared
in a few steps from aromatic aldehydes via the corresponding
esters obtained by Hemetsberger–Knittel synthesis and other
established methods of indole chemistry.[23] A novel approach
to indole-2-Weinreb amides starting from cinnamic acid Wein-
reb amides has been reported by us recently.[24] The remaining
part of ring A (the nitrogen atom, C-3, C-4, as well as the sub-
stituents located there) was to be introduced by means of one
single building block. An appropriately substituted isoxazole
(I/J) appeared most promising for this purpose. On the one
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hand it should be feasible to introduce isoxazoles at C-3 of the
indole building block by means of Pd-catalyzed cross-coupling
reactions, and on the other hand, reductive ring cleavage of
isoxazoles is known to give Z-enamino ketones.[25] The primary
enamino group obtained by reduction should undergo cyclo-
condensation with the acyl residue at C-2 of the indole directly
(or after treatment with an ammonia source) to provide carbon
atoms C-3 and C-4 of the envisaged -carboline. The other parts
of the isoxazole building block would provide the substituents
at C-3 and C-4 (Figure 2). The inevitable acyl group at C-4 of
the resulting -carbolines should offer the opportunity for a
broad spectrum of consecutive modifications (reduction, oxid-
ation, addition of nucleophiles) for the construction of novel,
even more complex residues at this position.
Figure 2. Attempted approach to highly substituted -carbolines via 2-acyl-
3-(isoxazol-4-yl)indoles (F) and envisaged routes for Pd-catalyzed cross-cou-
pling reactions of 2-acylindoles (G/H) and isoxazole (I/J) building blocks.
The first challenge in this project was to work out an effec-
tive protocol for the connection of the 2-acylindole and isox-
azole building blocks. To the best of our knowledge the synthe-
sis of 3-(isoxazol-4-yl)indoles (F) has been the subject of only
very few investigations, and only indole-N-protected com-
pounds were obtained in low yields by 1,3-dipolar cycloaddi-
tion reactions.[26] So we intended to work out an alternative
access via palladium-catalyzed biaryl synthesis. Three options
appeared promising for this purpose: route A) direct arylation
of 4-unsubstituted isoxazoles (I)[27] with 3-halogenated indoles
(G) under C–H activation, or routes B) and C) by Suzuki–Miyaura
cross-coupling of building blocks H and J, being either a 3-
borylated 2-acylindole and a 4-haloisoxazole, or a 3-halogen-
ated 2-acylindole and an isoxazole-4-boronic acid (or an ester
thereof )[28] (Figure 2).
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Results and Discussion
Route A appeared most attractive, since we already had 3-
bromo-2-acylindoles in hands from our previous investiga-
tions,[22a] and 3,5-disubstituted isoxazoles are readily available
following established methodologies, based on fundamental
work of Huisgen on 1,3-diplar cycloadditions.[25a,29,30] Unfortu-
nately, attempted couplings of 3,5-dimethylisoxazole with 2-
acetyl-3-bromoindole (1a) and 3-bromoindole-2-Weinreb
amide[22a] using published[27a] conditions resulted in negligible
conversions. Consequently, we focused on Suzuki–Miyaura
cross-coupling reactions. As mentioned above (Figure 2), two
different combinations of aromatic building blocks (3-borylated
2-acylindole + 4-haloisoxazole (route B) or 3-halogenated 2-
acylindole + 4-borylated isoxazole (route C)) were conceivable.
Following route B first, we intended to introduce a pinacol bor-
onate residue at C-3 of 2-acetylindole using a Masuda boryl-
ation.[31] Borylation of 2-acetyl-3-bromoindole (1a) with pina-
colborane (HBpin) under Pd(0) catalysis[32] failed completely,
whereas the N-SEM protected analogue 1b gave an inseparable
mixture of desired pinacol boronate 2b and debrominated
product 3. Nevertheless, we submitted the obtained mixture to
a Suzuki–Miyaura coupling with 4-bromo-3,5-dimethylisox-
azole. Since we could not detect the desired biaryl in the reac-
tion mixture, route B was abandoned (Scheme 1).
Scheme 1. Attempted borylations of 2-acetyl-3-bromoindoles 1a/1b.
Finally, route C was successful. The 4-borylated isoxazoles
required for this protocol can be built up de novo by regioselec-
tive 1,3-dipolar cycloaddition of nitrile oxides with alkynylbor-
onates,[32] by Blum's oxyboration of ynone oximes,[33] or are
obtained from 4-bromoisoxazoles via bromine-lithium ex-
change/trapping with trialkylborates[28] or by Pd-catalyzed Mi-
yaura borylation.[34] Initial experiments were performed with
commercially available isoxazole pinacolboronate 4a and 2-
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acetyl-3-bromoindole (1a).[22a] Only poor yields (<15 %) were
obtained in a first series of cross-coupling experiments using
Pd(0) and Pd(II) catalysts in combination with different phos-
phine ligands (PPh3, dppf, SPhos) and bases (DIPEA, K2CO3).
These frustrating experiments gave rise to the question
whether the free NH group of the indole prevented cross-cou-
pling. So we introduced the SEM protective group, which we
had identified as a very useful indole protective group in previ-
ous work.[35] But even SEM derivative 1b gave only slightly im-
proved yields (up to 20 %) under the cross-coupling conditions
examined with 1a before. Finally, further modifications of the
catalyst system led to the Pd(PPh3)4/Cs2CO3 system, which gave
a 61 % yield of the desired biaryl 5. With this intermediate in
hands the ring transformation reaction was examined. Reduc-
tive opening of the isoxazole ring was first attempted under
conditions (catalytic hydrogenation with Pd/C catalyst in
ethanolic KOH) which had given best results in our previously
published approach to canthin-4-ones involving a related ring
transformation.[36] But only a complex mixture of products was
obtained. Fortunately, hydrogenation in ethanol without added
base resulted in clean conversion (79 % yield) to the expected
Z-enamino ketone 6. The Z-configuration of the enamino ket-
one, which is stabilized by an intramolecular hydrogen bond,
obviously prevents direct cyclization to the desired -carboline
7 due to steric reasons. This prompted us to perform the hyd-
rogenation in presence of ammonium acetate, hoping that nu-
cleophilic addition/elimination of ammonia to the vinylogous
ketone moiety should in situ give an E-enamino ketone that
can undergo cyclocondensation with the acetyl group at C-2 of
the indole to give the -carboline 7. Cyclization did not occur
under these conditions, and once again the Z-enamino ketone
6 was isolated. Ring closure to the -carboline 7 was achieved
by heating the crude enamino ketone with ammonium acetate
in ethanol/acetic acid at 60 °C (87 % overall yield from 5).
Finally, we found that hydrogenation in presence of cesium
carbonate directly leads to the desired -carboline 7. Deprotec-
tion of the SEM group was achieved in 55 % yield (not opti-
mized) under standard conditions (TBAF, THF) to give the 1,3,4-
trisubstituted -carboline 8 (Scheme 2).
Having proven the feasibility of the new approach we in-
tended to reduce the number of steps of synthesis. To our de-
light the optimized Suzuki–Miyaura cross-coupling conditions
(Pd(PPh3)4/Cs2CO3 catalyst system) also worked with N-unpro-
tected 2-acyl-3-bromoindoles. Comparable results were ob-
tained with sodium carbonate here, but in contrast to cesium
carbonate, this base did not dissolve completely in the reaction
mixture. With alkyl, phenyl and heteroaryl (2-thienyl) ketones
(1a, 9a–g) the cross-coupling with 3,5-dimethylisoxazole-4-
pinacolboronate (4a) worked in acceptable yields (50–69 %) to
give biaryls 10, 11a–g. In contrast to the above mentioned
N-SEM derivative 5, the N-unsubstituted intermediate 10 did
not undergo reductive ring cleavage of the isoxazole moiety
under neutral conditions and with added ammonium acetate,
however in presence of Cs2CO3 once again smooth reductive
ring cleavage occurred, and fortunately, the formed Z-enamino
ketones underwent direct ring closure to the target -carbol-
ines 8, 12a–g under the reaction conditions in yields ranging
Full Paper
doi.org/10.1002/ejoc.202000230
EurJOC
European Journal of Organic Chemistry
Scheme 2. Synthesis of 1,3,4-trisubstituted -carboline 8 utilizing SEM-protec-
tion of the indole intermediates.
from 47–89 % (Scheme 3). In control experiments ammonium
acetate was added as an additional source of ammonia (com-
pare conversion of 6 into 7), but yields of the -carbolines were
not improved.
Scheme 3. Optimized, protective group-free synthesis of 1,3,4-trisubstituted
-carbolines.
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Finally, we investigated other isoxazole-4-boronates bearing
different aliphatic, aromatic and heteroaromatic residues at C-3
and C-5. The boronates 4b/4c were obtained from the corre-
sponding 3,5-disubstituted isoxazoles by bromination at C-4,[37]
followed by bromine-lithium exchange with n-butyllithium, and
trapping with B-isopropoxy-pinacolborane.[38] Subjecting these
boronates to cross-coupling with bromoindoles 1a/9d, followed
by reductive ring transformation (yields 68–88 %) gave the
highly substituted -carbolines 12h–k. To our surprise, the pyr-
idyl ketones arising from 5-pyridylisoxazole building block 4c
were further reduced to give the corresponding pyridyl carb-
inols 12j and 12k (Scheme 3).
The results are summarized in detail in Table 1 and Table 2.
Table 1. 3-(Isoxazol-4-yl)indoles 10,11a–k obtained via Suzuki–Miyaura cross-
coupling of indoles 1a,9a–g and isoxazole-4-boronates 4a–c.
Entry 1a, 9a–g 4a–c 10, 11a–k
1 1a 4a 10 55 %
R1 = CH3 R3 = R4 = CH3 R1 = R2 = R3 = CH3
R2 = H R2 = H
2 9a 4a 11a 69 %
R1 = n-C4H9 R1 = n-C4H9
R2 = H R2 = H
R3 = R4 = CH3
3 9b 4a 11b 65 %
R1 = phenyl R1 = phenyl
R2 = H R2 = H
R3 = R4 = CH3
4 9c 4a 11c 58 %
R1 = thiophen-2-yl R1 = thiophen-2-yl
R2 = H R2 = H
R3 = R4 = CH3
5 9d 4a 11d 57 %
R1 = CH3 R1 = R2 = R3 = CH3
R2 = OCH3 R2 = OCH3
6 9e 4a 11e 57 %
R1 = n-C4H9 R1 = n-C4H9
R2 = OCH3 R2 = OCH3
R3 = R4 = CH3
7 9f 4a 11f 58 %
R1 = phenyl R1 = phenyl
R2 = OCH3 R2 = OCH3
R3 = R4 = CH3
8 9g 4a 11g 50 %
R1 = thiophen-2-yl R1 = thiophen-2-yl
R2 = OCH3 R2 = OCH3
R3 = R4 = CH3
9 1a 4b 11h 60 %
R3 = CH3 R1 = R3 = CH3
R4 = phenyl R2 = H
R4 = phenyl
10 9d 4b 11i 61 %
R1 = R3 = CH3
R2 = OCH3
R4 = phenyl
11 1a 4c 11j 35 %
R3 = n-C3H7 R1 = CH3
R4 = 2-pyridyl R2 = H
R3 = n-C3H7
R4 = 2-pyridyl
12 9d 4c 11k 47 %
R1 = CH3
R2 = OCH3
R3 = n-C3H7
R4 = 2-pyridyl
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Table 2. Reductive ring transformation of 2-acyl-3-isoxazolylindoles 10, 11a–
k into -carbolines 8, 12a–k.
Conclusion
In conclusion, we have worked out a new and general protocol
for the synthesis of 1,3,4-trisubstituted -carbolines (with the
option for including additional substituents in the carbocyclic
ring C, if substituted indole precursors are utilized). Readily
available 2-acylindoles (aliphatic, aromatic, heteroaromatic acyl
residues are equally suitable) are easily brominated at C-3.
Suzuki–Miyaura cross-coupling with variously substituted and
readily available isoxazole-4-pinacol boronates gives biaryls,
which can be directly converted into the desired -carbolines
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upon Pd-catalyzed hydrogenation in presence of Cs2CO3 in the
sense of a reductive isoxazole-pyridine ring transformation. This
new method favorably compares with previously developed
methods for the synthesis of highly substituted -carbolines,
since it utilizes readily available building blocks, proceeds in
a small number of steps, and gives complex compounds with
predictable substitution patterns. In contrast to previously pub-
lished protocols for the synthesis of 3,4-disubstituted -carbol-
ines via reaction of internal alkynes and tert-butylimines of (3-
iodo)indole-2-carbaldehydes[13,14] via masked 1,5-dicarbonyl
compounds[21b] our method is advantageous since it needs nei-
ther protection of the keto group at C-2 of the indole nor of
the indole nitrogen. This new protocol should be of high inter-
est for the total synthesis of complex -carboline alkaloids and
synthetic -carbolines as drug candidates, hence opening new
opportunities for systematic investigations of structure-activity
relationships also including broad variation of substitution pat-
terns at ring A.
Experimental Section
Solvents used were of HPLC grade or p.a. grade and/or purified
according to standard procedures. All chemicals used were of ana-
lytical grade. Tetrahydrofuran was dried with sodium and distilled
before usage. Chloroform was dried with molecular sieves 3 Å. Melt-
ing points were determined by open tube capillary method on a
Büchi melting point B-450 apparatus and are uncorrected. IR meas-
urements were carried out with a Perkin-Elmer FTIR Paragon 1000
spectrometer or with a Jasco FT/IR-4100 as KBr pellets or as films.
NMR spectra were recorded on Avance III HD 400 MHz Bruker Bio-
Spin and Avance III HD 500 MHz Bruker BioSpin spectrometers.
Spectra were recorded in deuterated solvents and chemical shifts
are reported in parts per million (ppm). J values are given in Hertz.
Multiplicities are abbreviated as follows: s = singlet, d = doublet,
t = triplet, q = quartet, m = multiplet. Signal assignments were
carried out based on 1H, 13C, DEPT, HMQC, HMBC and COSY spectra.
NMR spectra were analyzed with the NMR software MestReNova,
Version 5.1.1–3092. Mass spectra were performed by electron im-
pact (EI) at 70 eV on a Thermo Finnigan MAT 95 or Jeol GCmate
II spectrometer or by electrospray ionization (ESI) using a Thermo
Finnigan LTQ FT Ultra Fourier Transform Ion Cyclotron resonance
mass spectrometer. All reactions were monitored by thin-layer chro-
matography (TLC) using pre-coated plastic sheets POLYGRAM® SIL
G/UV254 from Macherey-Nagel. Chromatographic purification of
products was performed by flash column chromatography (FCC) on
Merck silica gel 60 (0.015–0.040 mm). HPLC purities were deter-
mined using a HP Agilent 1100 HPLC with a diode array detector
and an InfinityLab Poroshell column (120 EC-CN, 4.6 × 150 mm, 4.6
Micron). The column flow was 1.0 mL/min and the temperature
50 °C. Either acetonitrile/water, 70:30 (method a), 50:50 (method b)
or 50:49.9 and 0.1 part 1.0 M formic acid (method c) was used as
eluent.
General Procedure 1: Suzuki–Miyaura cross-coupling of 2-acyl-3-
bromoindoles 1a,9a–g with 4-borylated isoxazoles 4a–c.
The 2-acyl-3-bromoindole 1a,9a–g (0.45–1.0 mmol), tetrakis(tri-
phenylphosphine)palladium(0) (10 mol-%) and the respective 4-bor-
ylated isoxazole 4a–c (2.0 equivalents) were dissolved in 1,4-diox-
ane (6 mL/mmol indole) under nitrogen atmosphere. Cesium carb-
onate (5 equivalents) was dissolved in water (2 mL/mmol) under a
nitrogen atmosphere and was added dropwise to the reaction mix-
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ture. The reaction mixture was heated at 75 °C for 19 h. After cool-
ing to room temperature the mixture was treated with saturated.
aqueous ammonium chloride solution (15 mL) and extracted with
ethyl acetate (3 × 20 mL). The combined organic layers were dried
with magnesium sulfate and the solvents were evaporated under
reduced pressure. Purification was accomplished by FCC.
General Procedure 2: Reductive ring cleavage and subsequent cy-
clization to -carbolines 8,12a–k.
The 2-acyl-3-isoxazolylindole 10,11a–k (0.15–0.30 mmol), palladium
on carbon (10 %) (100 mg/mmol starting material) and an excess
of cesium carbonate (1.5–3.0 equivalents) were disperged in anhy-
drous ethanol (2 mL). The reaction mixture was hydrogenated at
35 bar and 40 °C for 19 h. After cooling to room temperature, the
catalyst was filtered off through a pad of celite, washed with ethyl
acetate and the filtrate was evaporated under reduced pressure.
Purification was accomplished by FCC.
Synthesis and characterization of the compounds
1-{3-Bromo-1-[(2-(trimethylsilyl)ethoxy)methyl]1H-indol-2-
yl}ethan-1-one (1b): Under a nitrogen atmosphere 2-acetyl-3-bro-
moindole (1a) (470 mg, 1.97 mmol) was dissolved in anhydrous
tetrahydrofuran (6 mL). The solution was cooled to 0 °C and sodium
bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 2.59 mL,
2.59 mmol) was added. The mixture was stirred for 15 min, then
warmed up to room temperature and (trimethylsilyl)ethoxymethyl
chloride (SEM-chloride; 0.52 mL, 2.9 mmol) was added. The mixture
was stirred for another 2 h, then water (15 mL) was added and the
mixture extracted with ethyl acetate (3 × 20 mL). The combined
organic layers were dried with magnesium sulfate and the solvents
were evaporated under reduced pressure. Purification was accom-
plished by FCC using 12:1 hexanes/ethyl acetate to give 663 mg
(1.80 mmol, 91 %) of 1b as a yellow oil. 1H NMR (400 MHz, CDCl3):
δ = 7.70–7.67 (m, 1H, 4′-H), 7.56–7.53 (m, 1H, 7′-H), 7.43 (ddd, J =
8.4 Hz, 7.0 Hz, 1.2 Hz, 1H, 6′-H), 7.30–7.25 (m, 1H, 5′-H), 5.92 (s, 2H,
NCH2O), 3.53–3.48 (m, 2H, OCH2CH2), 2.86 (s, 3H, 2-H), 0.88–0.83 (m,
2H, OCH2CH2), –0.07 (s, 9H, Si(CH3)3) ppm. 13C NMR (101 MHz,
CDCl3): δ = 192.3 (C-1), 138.6 (C-7a′), 132.9 (C-2′), 127.4 (C-6′), 127.1
(C-3a′), 122.3 (C-5′), 121.9 (C-4′), 111.6 (C-7′), 101.6 (C-3′), 73.9
(NCH2O), 66.0 (OCH2CH2), 32.1 (C-2), 18.0 (OCH2CH2), –1.3 (Si(CH3)3)
ppm. IR (film): ν˜ = 3056, 2952, 2895, 1665, 1497, 1473, 1376, 1337,
1248, 1202, 1084, 860, 836, 744 cm–1. HRMS (EI): m/z = 367.0600
[M·]+ (calcd for C16H22BrNO2Si·+: 367.0598). HPLC purity (method b):
95 % (λ = 210 nm), > 99 % (λ = 254 nm).
3-Methyl-5-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)isoxazole (4b): A solution of 3-methyl-5-phenylisoxazole
(557 mg, 3.50 mmol) and N-bromosuccinimide (664 mg, 3.75 mmol)
in glacial acetic acid (5 mL) was heated at 100 °C for 3 h. After
cooling to room temperature 2 N sodium hydroxide solution (15 mL)
was added and the mixture extracted with ethyl acetate
(3 × 20 mL). The combined organic layers were dried with magne-
sium sulfate and the solvents were evaporated under reduced pres-
sure. Purification was accomplished by FCC using 6:1 hexanes/ethyl
acetate to give 710 mg (2.98 mmol, 85 %) of 4-bromo-3-methyl-5-
phenylisoxazole as a white solid, which was directly converted into
the boronic acid pinacol ester as follows: A solution of 4-bromo-3-
methyl-5-phenylisoxazole (360 mg, 1.51 mmol) in anhydrous tetra-
hydrofuran (4 mL) was cooled to –78 °C and n-butyllithium solution
(2.5 M in hexanes, 0.91 mL, 2.3 mmol) was added. After stirring
at –78 °C for 1 h the mixture was warmed up to room temperature,
2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.54 mL,
7.56 mmol) was added, and the mixture was stirred at room temper-
ature for further 1.5 h. Then water (15 mL) was added and the
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mixture was extracted with ethyl acetate (3 × 20 mL). The combined
organic layers were dried with magnesium sulfate and the solvents
evaporated under reduced pressure. Purification was accomplished
by FCC using 6:1 hexanes/ethyl acetate to give 319 mg (1.12 mmol,
74 %) of 4b as a white solid. Mp 71 °C. 1H NMR (400 MHz, CDCl3):
δ = 8.05–8.01 (m, 2H, 2′-H, 6′-H), 7.46–7.41 (m, 3H, 3′-H, 4′-H, 5′-H),
2.43 (s, 3H, 3-CH3), 1.34 (s, 12H, 4′′-(CH3)2, 5′′-(CH3)2 ppm. 13C NMR
(101 MHz, CDCl3): δ = 175.8 (C-5), 165.1 (C-3), 130.4 (C-4′), 128.6 (C-
1′), 128.4 (C-2′, C-3′, C-5′, C-6′), 102.3 (br, C-4), 83.9 (C-4′′, C-5′′), 25.0
(4′′-(CH3)2, 5′′-(CH3)2), 12.4 (3-CH3) ppm. IR (KBr): ν˜ = 3074, 2976,
2935, 1611, 1574, 1486, 1412, 1338, 1143, 1061, 962, 855, 779, 723,
691 cm–1. HRMS (ESI) : m/z = 286.1608 [M + H]+ (calcd for
C16H21BNO3+: 286.1609). HPLC purity (method b): 99 % (λ =
210 nm), 99 % (λ = 254 nm).
3-Propyl-5-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxabor-
olan-2-yl)isoxazole (4c): Under a nitrogen atmosphere N-chloro-
succinimide (1.58 g, 11.8 mmol) was dissolved in anhydrous chloro-
form (10 mL), then n-butyraldoxime (1.11 mL, 11.6 mmol) and pyrid-
ine (78 μL, 0.97 mmol) was added dropwise. The reaction mixture
was heated at 50 °C for 1 h. Then 2-ethynylpyridine (0.98 mL,
9.7 mmol) and triethylamine (2.00 mL, 14.3 mmol) was added drop-
wise. The mixture was stirred for further 1.5 h at 50 °C. After cooling
to room temperature water (20 mL) was added and the mixture
extracted with dichloromethane (3 × 25 mL). The combined organic
layers were dried with magnesium sulfate and the solvents were
evaporated under reduced pressure. Purification was accomplished
by FCC using 4:1 hexanes/ethyl acetate to give 1.36 g (7.23 mmol,
75 %) 3-propyl-5-(pyridin-2-yl)isoxazole as a yellow oil. This isox-
azole (599 mg, 3.18 mmol) and N-bromosuccinimide (566 mg,
3.18 mmol) were dissolved in glacial acetic acid (5 mL) and the
mixture was heated at 80 °C for 18 h. After cooling to room temper-
ature 2 N sodium hydroxide solution (20 mL) was added and ex-
tracted with ethyl acetate (3 × 25 mL). The combined organic layers
were dried with magnesium sulfate and the solvents were evapo-
rated under reduced pressure. Purification was accomplished by
FCC using 4:1 hexanes/ethyl acetate to give 507 mg (1.90 mmol,
60 %) of 4-bromo-3-propyl-5-(pyridin-2-yl)isoxazole as a pale yellow
oil. A solution of this isoxazole (213 mg, 0.797 mmol) in anhydrous
tetrahydrofuran (3 mL) was cooled to –78 °C and n-butyllithium
solution (2.5 M in hexanes, 0.42 mL, 1.1 mmol) was added. After
stirring at –78 °C for 1 h the mixture was warmed up to room
temperature, 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(0.50 mL, 2.4 mmol) was added, and the mixture was stirred at room
temperature for further 1.5 h. Then water (15 mL) was added and
the mixture was extracted with ethyl acetate (3 × 20 mL). The com-
bined organic layers were dried with magnesium sulfate and the
solvents evaporated under reduced pressure. Purification was ac-
complished by FCC using 3:1 hexanes/ethyl acetate to give 236 mg
(0.751 mmol, 94 %) of 4c as a pale yellow solid. Mp 126 °C. 1H NMR
(400 MHz, CDCl3): δ = 8.60 (ddd, J = 4.8 Hz, 1.7 Hz, 1.0 Hz, 1H,
3′-H), 7.95–7.91 (m, 1H, 6′-H), 7.79–7.74 (m, 1H, 5′-H), 7.29 (ddd, J =
7.6 Hz, 4.8 Hz, 1.2 Hz, 1H, 4′-H), 2.76–2.71 (m, 2H, 1′′-H), 1.81–1.70
(m, 2H, 2′′-H), 1.40 (s, 12H, 4′′′-(CH3)2, 5′′′-(CH3)2), 1.00 (t, J = 7.4 Hz,
3H, 3′′-H) ppm. 13C NMR (101 MHz, CDCl3): δ = 172.8 (C-5), 167.4
(C-3), 149.5 (C-3′), 147.3 (C-1′), 136.8 (C-5′), 124.3 (C-4′), 121.6
(C-6′), 104.7 (br, C-4), 84.2 (C-4′′′, C-5′′′), 28.7 (C-1′′), 24.9 (4′′′-(CH3)2,
5′′′-(CH3)2), 22.3 (C-2′′), 14.0 (C-3′′) ppm. IR (KBr): ν˜ = 3330, 3065,
2961, 2870, 1579, 1564, 1415, 1310, 1143, 1069, 856, 796, 744 cm–1.
HRMS (EI): m/z = 314.1784 [M·]+ (calcd for C17H23BN2O3·+: 314.1796).
HPLC purity (method c): 97 % (λ = 210 nm), 97 % (λ = 254 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-1-{[2-(trimethylsilyl)ethoxy]-
methyl}-1H-indol-2-yl]ethan-1-one (5): Prepared from 1b
(366 mg, 0.994 mmol), tetrakis(triphenylphosphine)palladium(0)
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(116 mg, 0.100 mmol), 3,5-dimethylisoxazole-4-pinacolboronate
(4a) (445 mg, 1.99 mmol) and cesium carbonate (1.80 g, 5.52 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 9:1 hexanes/ethyl acetate to give 233 mg (0.606 mmol,
61 %) of 5 as a yellow oil. 1H NMR (500 MHz, CDCl3): δ = 7.60 (d,
J = 8.5 Hz, 1H, 7′-H), 7.44 (ddd, J = 8.4 Hz, 6.9 Hz, 1.2 Hz, 1H, 6′-H),
7.31–7.28 (m, 1H, 4′-H), 7.20 (ddd, J = 7.9 Hz, 7.0 Hz, 0.8 Hz, 1H,
5′-H), 5.97 (s, 2H, NCH2O), 3.58–3.53 (m, 2H, OCH2CH2), 2.28 (s, 3H,
5′′-CH3), 2.24 (s, 3H, 2-H), 2.11 (s, 3H, 3′′-CH3), 0.89–0.85 (m, 2H,
OCH2CH2), –0.09 (s, 9H, Si(CH3)3) ppm. 13C NMR (126 MHz, CDCl3):
δ = 192.8 (C-1), 167.1 (5′′-CH3), 160.0 (3′′-CH3), 139.1 (C-7a′), 134.2
(C-2′), 127.4 (C-3a′), 126.9 (C-6′), 122.1 (C-5′), 121.3 (C-4′), 113.1
(C-3′), 111.7 (C-7′), 109.7 (C-4′′), 73.7 (NCH2O), 66.1 (OCH2CH2), 30.3
(C-2), 18.0 (OCH2CH2), 11.6 (5′′-CH3), 10.7 (3′′-CH3), –1.4 (Si(CH3)3)
ppm. IR (film): ν˜ = 3057, 2952, 2856, 1665, 1456, 1335, 1248, 1169,
1151, 1081, 859, 837, 747 cm–1. HRMS (EI): m/z = 384.1860 [M] (calcd
for C21H28N2O3Si: 384.1869). HPLC purity (method 2c): > 99 % (λ =
210 nm), > 99 % (λ = 254 nm).
(Z)-3-{2-Acetyl-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-indol-3-
yl}4-aminopent-3-en-2-one (6) : Intermediate 5 (53 mg,
0.14 mmol) and palladium on carbon (17 mg, 0.016 mmol) were
dispersed in anhydrous ethanol (2 mL) and hydrogenated at 30 bar
and room temperature for 19 h. Then the catalyst was filtered off
through a pad of celite, washed with ethyl acetate and the filtrate
was evaporated under reduced pressure. Purification was accom-
plished by FCC using 4:1 hexanes/ethyl acetate and 5 % triethyl-
amine to give 42 mg (0.11 mmol, 79 %) of 6 as a yellow oil. 1H NMR
(400 MHz, CD2Cl2): δ = 10.76 (s, 1H, NH2), 7.56 (d, J = 8.0 Hz, 1.0 Hz,
1H, 7′-H), 7.53–7.49 (m, 1H, 4′-H), 7.40 (ddd, J = 8.3 Hz, 7.0 Hz,
1.2 Hz, 1H, 6′-H), 7.19 (ddd, J = 7.9 Hz, 7.0 Hz, 0.9 Hz, 1H, 5′-H), 5.97
(d, J = 2.8 Hz, 2H, NCH2O), 5.50 (s, 1H, NH2), 3.48–3.42 (m,
2H,OCH2CH2), 2.43 (s, 3H, 2′′-H), 1.76 (s, 3H, 1-H), 1.66 (s, 3H, 5-H),
0.84–0.79 (m, 2H, OCH2CH2), –0.12 (s, 9H, Si(CH3)3) ppm. 13C NMR
(101 MHz, CD2Cl2): δ = 196.8 (C-2), 193.4 (C-1′′), 161.4 (C-4), 139.8
(C-7a′), 134.7 (C-2′), 128.8 (C-3a′), 126.9 (C-6′), 125.2 (C-3′), 122.2
(C-4′), 121.9 (C-5′), 111.8 (C-7′), 99.9 (C-3), 74.1 (NCH2O), 66.1
(OCH2CH2), 30.8 (C-2′′), 28.8 (C-1), 22.0 (C-5), 18.4 (OCH2CH2), –1.3
(Si(CH3)3) ppm. IR (film): ν˜ = 3382, 3057, 2953, 2923, 2859, 1701,
1615, 1568, 1362, 1249, 1073, 859, 737 cm–1. HRMS (EI): m/z =
386.2032 [M] (calcd for C21H30N2O3Si: 386.2026). HPLC purity not
determined due to limited stability of the compound.
1-{1,3-Dimethyl-9-[(2-(trimethylsilyl)ethoxy)methyl]-9H-pyrido-
[3,4-b]indol-4-yl}ethan-1-one (7): Method A: Isoxazolylindole 5
(56 mg, 0.15 mmol), palladium on carbon (16 mg, 0.015 mmol) and
ammonium acetate (146 mg, 1.89 mmol) in anhydrous ethanol
(2 mL) was hydrogenated at 30 bar and room temperature for 6.5 h.
Then glacial acetic acid (1 mL) was added and the mixture was
heated at 60 °C for further 2 h. After cooling to room temperature
the catalyst was filtered off through a pad of celite, washed with
ethyl acetate and the filtrate was evaporated under reduced pres-
sure to give 48 mg (0.13 mmol, 87 %) of 7 as a yellow oil.
Method B: Prepared from 5 (18 mg, 0.047 mmol), palladium on
carbon (6 mg, 0.006 mmol) and cesium carbonate (53 mg,
0.16 mmol) following General Procedure 2. Purification was accom-
plished by FCC using 4:1 hexanes/ethyl acetate and 5 % triethyl-
amine to give 14 mg (0.038 mmol, 81 %) of 7 as a pale yellow oil.
1H NMR (500 MHz, CD2Cl2): δ = 7.80 (d, J = 8.0 Hz, 1H, 5′-H), 7.62–
7.55 (m, 2H, 7′-H, 8′-H), 7.24 (ddd, J = 8.0 Hz, 6.6 Hz, 1.5 Hz, 1H,
6′-H), 5.82 (s, 2H, NCH2O), 3.59–3.52 (m, 2H, OCH2CH2), 3.02 (s, 3H,
1′-CH3), 2.70 (s, 3H, 2-H), 2.56 (s, 3H, 3′-CH3), 0.91–0.87 (m, 2H,
OCH2CH2), –0.08 (s, 9H, Si(CH3)3) ppm. 13C NMR (126 MHz, CD2Cl2):
δ = 206.6 (C-1), 143.1 (C-1′, C-8a′), 141.7 (C-3′), 133.9 (C-9a′), 129.0
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(C-7′), 128.4 (C-4′), 126.0 (C-4a′), 123.2 (C-5′), 121.1 (C-6′), 120.3 (C-
4b′), 110.6 (C-8′), 73.8 (NCH2O), 66.5 (OCH2CH2), 32.7 (C-2), 23.4
(1′-CH3), 21.8 (3′-CH3), 18.4 (OCH2CH2), –1.3 (Si(CH3)3) ppm. IR (film):
ν˜ = 3057, 2953, 2898, 1700, 1615, 1567, 1447, 1362, 1249, 1216,
1073, 860, 837, 738 cm–1. HRMS (EI): m/z = 368.1927 [M] (calcd for
C21H28N2O2Si: 368.1920). HPLC purity (method c): > 99 % (λ =
210 nm), > 99 % (λ = 245 nm).
1-(1,3-Dimethyl-9H-pyrido[3,4-b]indol-4-yl)ethan-1-one (8):
Method A: Under a nitrogen atmosphere 121 mg (0.328 mmol) N-
SEM derivative 7 was dissolved in anhydrous tetrahydrofuran (3 mL)
and tetrabutylammonium fluoride solution (1.0 M in tetrahydro-
furan, 0.99 mL, 0.99 mmol) was added. The mixture was heated at
70 °C for 19 h. After cooling to room temperature water (15 mL)
was added and the mixture was extracted with ethyl acetate
(3 × 20 mL). The combined organic layers were dried with magne-
sium sulfate and the solvents were evaporated under reduced pres-
sure. Purification was accomplished by FCC using 1:1 hexanes/acet-
one to give 42 mg of 8 (0.18 mmol, 55 %) as a yellow solid.
Method B: Prepared from 10 (68 mg, 0.27 mmol), palladium on
carbon (29 mg, 0.027 mmol) and cesium carbonate (261 mg,
0.801 mmol) following General Procedure 2. Purification was accom-
plished by FCC using 1:3 hexanes/ethyl acetate to give 59 mg
(0.25 mmol, 93 %) of 8 as a yellow solid. Mp 145 °C. 1H NMR
(500 MHz, CD2Cl2): δ = 8.66 (s, 1H, NH), 7.86–7.82 (m, 1H, 5′-H),
7.54–7.51 (m, 2H, 7′-H, 8′-H), 7.22 (ddd, J = 8.1 Hz, 5.6 Hz, 2.5 Hz,
1H, 6′-H), 2.76 (s, 3H, 1′-CH3), 2.72 (s, 3H, 2-H), 2.59 (s, 3H, 3′-CH3)
ppm. 13C NMR (126 MHz, CD2Cl2): δ = 206.4 (C-1), 142.5 (C-1′), 141.6
(C-3′), 141.2 (C-8a′), 133.3 (C-9a′), 128.9 (C-7′), 128.3 (C-4′), 124.6 (C-
4a′), 123.3 (C-5′), 120.8 (C-4b′, C-6′), 112.3 (C-8′), 32.6 (C-2), 22.0
(3′-CH3), 20.6 (1′-CH3) ppm. IR (KBr): ν˜ = 3367, 3134, 3061, 2922,
1696, 1621, 1498, 1404, 1289, 1232, 1184, 961, 741 cm–1. HRMS (EI):
m/z = 238.1105 [M] (calcd for C15H14N2O: 238.1106). HPLC purity
(method c): 97 % (λ = 210 nm), 95 % (λ = 254 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-1H-indol-2-yl]ethan-1-one (10):
Prepared from 2-acetyl-3-bromoindole (1a) (104 mg, 0.437 mmol),
tetrakis(triphenylphosphine)palladium(0) (50 mg, 0.043 mmol), 3,5-
dimethylisoxazole-4-pinacolboronate (4a) (202 mg, 0.906 mmol)
and cesium carbonate (708 mg, 2.17 mmol) following General Pro-
cedure 1. Purification was accomplished by FCC using 3:1 hexanes/
ethyl acetate to give 61 mg (0.24 mmol, 55 %) of 10 as a yellow
solid. Mp 186 °C. 1H NMR (500 MHz, CDCl3): δ = 9.43 (s, 1H, NH),
7.50–7.47 (m, 1H, 7′-H), 7.41 (ddd, J = 8.3 Hz, 6.9 Hz, 1.1 Hz, 1H,
6′-H), 7.33 (dd, J = 8.1 Hz, 0.9 Hz, 1H, 4′-H), 7.17 (ddd, J = 8.0 Hz,
6.9 Hz, 1.0 Hz, 1H, 5′-H), 2.30 (s, 3H, 5′′-CH3), 2.26 (s, 3H, 2-H), 2.13
(s, 3H, 3′′-CH3) ppm. 13C NMR (126 MHz, CDCl3): δ = 190.5 (C-1),
167.3 (C-5′′), 160.1 (C-3′′), 136.1 (C-7a′), 133.7 (C-2′), 128.8 (C-3a′),
127.1 (C-6′), 121.7 (C-4′), 121.5 (C-5′), 112.4 (C-7′), 110.6 (C-3′), 109.2
(C-4′′), 27.4 (C-2), 11.7 (5′′-CH3), 10.7 (3′′-CH3) ppm. IR (KBr): ν˜ =
3381, 3060, 2918, 2849, 1706, 1650, 1534, 1405, 1330, 1233, 957,
736 cm–1. HRMS (ESI) : m/z = 255.1128 [M + H]+ (calcd for
C15H15N2O2+: 255.1128). HPLC purity (method a): 98 % (λ = 210 nm),
> 99 % (λ = 254 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-1H-indol-2-yl]pentan-1-one
(11a): Prepared from 2-pentanoyl-3-bromoindole (9a) (154 mg,
0.550 mmol), tetrakis(triphenylphosphine)palladium(0) (65 mg,
0.056 mmol), 3,5-dimethylisoxazole-4-pinacolboronate (4a)
(251 mg, 1.13 mmol) and cesium carbonate (895 mg, 2.75 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 6:1 hexanes/ethyl acetate to give 112 mg (0.378 mmol,
69 %) of 11a as a yellow solid. Mp 142 °C. 1H NMR (500 MHz,
CD2Cl2): δ = 9.60 (s, 1H, NH), 7.51 (d, J = 8.3 Hz, 1H, 7′-H), 7.39 (ddd,
J = 8.2 Hz, 6.9 Hz, 1.1 Hz, 1H, 6′-H), 7.35–7.32 (m, 1H, 4′-H), 7.15
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(ddd, J = 8.0 Hz, 7.0 Hz, 0.8 Hz, 1H, 5′-H), 2.57–2.52 (m, 2H, 2-H),
2.28 (s, 3H, 5′′-CH3), 2.10 (s, 3H, 3′′-CH3), 1.62–1.55 (m, 2H, 3-H),
1.30–1.20 (m, 2H, 4-H), 0.84 (t, J = 7.4 Hz, 3H, 5-H) ppm. 13C NMR
(126 MHz, CD2Cl2): δ = 193.9 (C-1), 167.6 (C-5′′), 160.4 (C-3′′), 136.5
(C-7a′), 134.0 (C-2′), 129.3 (C-3a′), 127.1 (C-6′), 122.0 (C-4′), 121.7 (C-
5′), 112.7 (C-7′), 110.1 (C-3′), 109.7 (C-4′′), 39.6 (C-2), 27.0 (C-3), 22.9
(C-4), 14.1 (C-5), 11.9 (5′′-CH3), 10.8 (3′′-CH3) ppm. IR (KBr): ν˜ = 3284,
3060, 2954, 2930, 2870, 1657, 1538, 1403, 1340, 1197, 1067, 956,
890, 739 cm–1. HRMS (ESI) : m/z = 295.1455 [M – H]– (calcd
for C18H19N2O2–: 295.1452). HPLC purity (method a): > 99 % (λ =
210 nm), > 99 % (λ = 254 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-1H-indol-2-yl](phenyl)-methan-
one (11b): Prepared from 2-benzoyl-3-bromoindole (9b) (133 mg,
0.443 mmol), tetrakis(triphenylphosphine)palladium(0) (50 mg,
0.043 mmol), 3,5-dimethylisoxazole-4-pinacolboronate (4a)
(193 mg, 0.865 mmol) and cesium carbonate (706 mg, 2.17 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 4:1 hexanes/ethyl acetate to give 91 mg (0.29 mmol,
65 %) of 11b as a yellow solid. Mp 191 °C. 1H NMR (400 MHz,
CD2Cl2): δ = 9.67 (s, 1H, NH), 7.59–7.55 (m, 3H, 7-H, 2′-H, 6′-H), 7.51–
7.46 (m, 1H, 4′-H), 7.45–7.40 (m, 2H, 4-H, 6-H), 7.34–7.29 (m, 2H,
3′-H, 5′-H), 7.20 (ddd, J = 7.9 Hz, 7.0 Hz, 1.0 Hz, 1H, 5-H), 2.04 (s, 3H,
5′′-CH3), 2.01 (s, 3H, 3′′-CH3) ppm. 13C NMR (101 MHz, CD2Cl2): δ =
189.2 (C=O), 167.0 (C-5′′), 159.8 (C-3′′), 138.1 (C-1′), 137.2 (C-7a),
132.9 (C-2, C-4′), 129.4 (C-2′, C-6′), 128.6 (C-3a), 128.3 (C-3′, C-5′),
127.3 (C-6), 122.2 (C-4), 121.9 (C-5), 112.9 (C-7), 111.9 (C-3), 110.0
(C-4′′), 11.7 (5′′-CH3), 10.9 (3′′-CH3) ppm. IR (KBr): ν˜ = 3320, 3065,
2923, 1608, 1573, 1427, 1406, 1335, 1262, 1147, 1021, 737, 697 cm–1.
HRMS (ESI): m/z = 317.1283 [M + H]+ (calcd for C20H17N2O2+:
317.1285). HPLC purity (method c): 99 % (λ = 210 nm), 99 % (λ =
254 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-1H-indol-2-yl](thiophen-2-yl)-
methanone (11c): Prepared from 2-acyl-3-bromoindole 9c (200 mg,
0.653 mmol), tetrakis(triphenylphosphine)palladium(0) (76 mg,
0.066 mmol), 3,5-dimethylisoxazole-4-pinacolboronate (4a)
(291 mg, 1.30 mmol) and cesium carbonate (1.06 g, 3.25 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 4:1 hexanes/ethyl acetate to give 122 mg (0.378 mmol,
58 %) of 11c as a yellow solid. Mp 205 °C. 1H NMR (400 MHz,
CD2Cl2): δ = 9.41 (s, 1H, NH), 7.67 (dd, J = 4.9 Hz, 1.1 Hz, 1H, 3′-H),
7.56–7.53 (m, 1H, 7-H), 7.46–7.40 (m, 2H, 4-H, 6-H), 7.38 (dd, J =
3.8 Hz, 1.1 Hz, 1H, 5′-H), 7.21 (ddd, J = 8.1 Hz, 7.1 Hz, 1.0 Hz, 1H, 5-
H), 7.01 (dd, J = 4.9 Hz, 3.8 Hz, 1H, 4′-H), 2.20 (s, 3H, 5′′-CH3), 2.07
(s, 3H, 3′′-CH3) ppm. 13C NMR (101 MHz, CD2Cl2): δ = 180.1 (C=O),
167.3 (C-5′′), 160.2 (C-3′′), 142.7 (C-1′), 136.9 (C-7a), 134.4 (C-3′,
C-5′), 132.9 (C-2), 128.5 (C-3a), 128.2 (C-4′), 127.0 (C-6), 122.1 (C-4),
121.9 (C-5), 112.8 (C-7), 110.6 (C-3), 110.1 (C-4′′), 12.0 (5′′-CH3), 11.0
(3′′-CH3) ppm. IR (KBr): ν˜ = 3302, 3061, 2922, 1594, 1515, 1410, 1334,
1266, 1179, 1049, 855, 740 cm–1. HRMS (EI): m/z = 322.0761 [M]
(calcd for C18H14N2O2S: 322.0776). HPLC purity (method b): > 99 %
(λ = 210 nm), > 99 % (λ = 254 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-5-methoxy-1H-indol-2-yl]-
ethan-1-one (11d): Prepared from 2-acyl-3-bromoindole 9d
(131 mg, 0.489 mmol), tetrakis(triphenylphosphine)palladium(0)
(58 mg, 0.050 mmol), 3,5-dimethylisoxazole-4-pinacolboronate (4a)
(219 mg, 0.982 mmol) and cesium carbonate (801 mg, 2.46 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 3:1 hexanes/ethyl acetate to give 79 mg (0.28 mmol,
57 %) of 11d as a yellow solid. Mp 187 °C. 1H NMR (400 MHz,
CD2Cl2): δ = 9.36 (s, 1H, NH), 7.41–7.37 (m, 1H, 7′-H), 7.05 (dd, J =
9.0 Hz, 2.5 Hz, 1H, 6′-H), 6.67 (d, J = 2.4 Hz, 1H, 4′-H), 3.76 (s, 3H,
OCH3), 2.29 (s, 3H, 5′′-CH3), 2.21 (s, 3H, 2-H), 2.11 (s, 3H, 3′′-CH3)
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ppm. 13C NMR (101 MHz, CD2Cl2): δ = 190.4 (C-1), 167.7 (C-5′′), 160.6
(C-3′′), 155.8 (C-5′), 134.7 (C-2′), 131.8 (C-7a′), 129.7 (C-3a′), 119.2 (C-
6′), 113.8 (C-7′), 110.3 (C-3′), 109.7 (C-4′′), 101.4 (C-4′), 56.2 (OCH3),
27.6 (C-2), 11.9 (5′′-CH3), 10.9 (3′′-CH3) ppm. IR (KBr): ν˜ = 3308, 3060,
2928, 1645, 1529, 1500, 1468, 1406, 1270, 1223, 1166, 1029, 806 cm–1.
HRMS (ESI): m/z = 283.1086 [M – H]– (calcd for C16H15N2O3–:
283.1088). HPLC purity (method c): > 99 % (λ = 210 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-5-methoxy-1H-indol-2-yl]pent-
an-1-one (11e): Prepared from 2-acyl-3-bromoindole 9e (138 mg,
0.445 mmol), tetrakis(triphenylphosphine)palladium(0) (57 mg,
0.049 mmol), 3,5-dimethylisoxazole-4-pinacolboronate (4a)
(204 mg, 0.914 mmol) and cesium carbonate (802 mg, 2.46 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 6:1 hexanes/ethyl acetate to give 83 mg (0.25 mmol,
56 %) of 11e as a yellow solid. Mp 188 °C. 1H NMR (500 MHz,
(CD3)2SO): δ = 11.90 (s, 1H, NH), 7.43 (d, J = 8.9 Hz, 1H, 7′-H), 6.99
(dd, J = 8.9 Hz, 2.4 Hz, 1H, 6′-H), 6.62 (d, J = 2.4 Hz, 1H, 4′-H), 3.71
(s, 3H, OCH3), 2.71–2.60 (m, 2H, 2-H), 2.22 (s, 3H, 5′′-CH3), 2.00 (s,
3H, 3′′-CH3), 1.55–1.48 (m, 2H, 3-H), 1.27–1.19 (m, 2H, 4-H), 0.81 (t,
J = 7.4 Hz, 3H, 5-H) ppm. 13C NMR (126 MHz, (CD3)2SO): δ = 192.6
(C-1), 166.2 (C-5′′), 159.6 (C-3′′), 154.5 (C-5′), 133.3 (C-2′), 131.6
(C-7a′), 127.8 (C-3a′), 117.6 (C-6′), 114.1 (C-7′), 109.3 (C-4′′), 107.6
(C-3′), 100.0 (C-4′), 55.3 (OCH3), 38.7 (C-2), 26.0 (C-3), 21.8 (C-4), 13.6
(C-5), 11.4 (5′′-CH3), 10.3 (3′′-CH3) ppm. IR (KBr): ν˜ = 3311, 3064,
2964, 2926, 1630, 1499, 1461, 1406, 1227, 1161, 1025, 813 cm–1.
HRMS (ESI): m/z = 325.1556 [M – H]– (calcd for C19H21N2O3–:
325.1558). HPLC-purity (method c): 96 % (λ = 210 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-5-methoxy-1H-indol-2-yl]-
(phenyl)methanone (11f): Prepared from 2-acyl-3-bromoindole 9f
(149 mg, 0.451 mmol), tetrakis(triphenylphosphine)palladium(0)
(52 mg, 0.045 mmol), 3,5-dimethylisoxazole-4-pinacolboronate (4a)
(218 mg, 0.977 mmol) and cesium carbonate (735 mg, 2.26 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 4:1 hexanes/ethyl acetate to give 89 mg (0.26 mmol,
58 %) of 11f as a yellow solid. Mp 201 °C. 1H NMR (400 MHz,
CD2Cl2): δ = 9.39 (s, 1H, NH), 7.56–7.53 (m, 2H, 2′-H, 6′-H), 7.50–7.43
(m, 2H, 7-H, 4′-H), 7.33–7.28 (m, 2H, 3′-H, 5′-H), 7.08 (dd, J = 9.0 Hz,
2.4 Hz, 1H, 6-H), 6.73 (d, J = 2.4 Hz, 1H, 4-H), 3.78 (s, 3H, OCH3), 2.04
(s, 3H, 5′′-CH3), 2.01 (s, 3H, 3′′-CH3) ppm. 13C NMR (101 MHz,
CD2Cl2): δ = 188.8 (C=O), 167.0 (C-5′′), 159.9 (C-3′′), 155.9 (C-5), 138.2
(C-1′), 133.4 (C-2), 132.8 (C-4′), 132.4 (C-7a), 129.3 (C-2′, C-6′), 129.1
(C-3a), 128.3 (C-3′, C-5′), 119.2 (C-6), 113.9 (C-7), 111.4 (C-3), 110.1
(C-4′′), 101.6 (C-4), 56.2 (OCH3), 11.8 (5′′-CH3), 10.9 (3′′-CH3) ppm. IR
(KBr): ν˜ = 3359, 3297, 3057, 2964, 1614, 1574, 1498, 1462, 1407,
1262, 1226, 1153, 1018, 809, 734 cm–1. HRMS (EI): m/z = 346.1315
[M] (calcd for C21H18N2O3: 346.1317). HPLC purity (method b): 96 %
(λ = 210 nm).
1-[3-(3,5-Dimethylisoxazol-4-yl)-5-methoxy-1H-indol-2-yl](thio-
phen-2-yl)methanone (11g): Prepared from 2-acyl-3-bromoindole
9g (214 mg, 0.636 mmol), tetrakis(triphenylphosphine)palladium(0)
(92 mg, 0.080 mmol), 3,5-dimethylisoxazole-4-pinacolboronate (4a)
(296 mg, 1.32 mmol) and cesium carbonate (1.04 g, 3.18 mmol)
following General Procedure 1. Purification was accomplished by
FCC using 4:1 hexanes/ethyl acetate to give 112 mg (0.318 mmol,
50 %) of 11g as a yellow solid. Mp 186 °C. 1H NMR (400 MHz, CDCl3):
δ = 9.91 (s, 1H, NH), 7.61 (dd, J = 4.9 Hz, 1.0 Hz, 1H, 3′-H), 7.46 (d,
J = 9.0 Hz, 1H, 7-H), 7.36 (dd, J = 3.8 Hz, 1.0 Hz, 1H, 5′-H), 7.09 (dd,
J = 9.0 Hz, 2.4 Hz, 1H, 6-H), 6.97 (dd, J = 4.8 Hz, 3.9 Hz, 1H, 4′-H),
6.73 (d, J = 2.3 Hz, 1H, 4-H), 3.81 (s, 3H, OCH3), 2.21 (s, 3H, 5′′-CH3),
2.12 (s, 3H, 3′′-CH3) ppm. 13C NMR (101 MHz, CDCl3): δ = 179.8
(C=O), 166.8 (C-5′′), 160.0 (C-3′′), 155.4 (C-5), 142.2 (C-1′), 134.0 (C-
3′), 133.9 (C-5′), 132.9 (C-2), 132.1 (C-7a), 128.4 (C-3a), 127.8 (C-4′),
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118.7 (C-6), 113.7 (C-7), 109.9 (C-4′′), 109.7 (C-3), 101.1 (C-4), 55.8
(OCH3), 11.7 (5′′-CH3), 10.8 (3′′-CH3) ppm. IR (KBr): ν˜ = 3295, 2932,
1587, 1497, 1409, 1261, 1223, 1149, 1051, 856, 747 cm–1. HRMS
(ESI): m/z = 353.0952 [M + H]+ (calcd for C19H17N2O3S+: 353.0954).
HPLC purity (method b): > 99 % (λ = 210 nm), > 99 % (254 nm).
1-[3-(3-Methyl-5-phenylisoxazol-4-yl)-1H-indol-2-yl]ethan-1-
one (11h): Prepared from 2-acyl-3-bromoindole 1a (174 mg,
0.73 mmol), tetrakis(triphenylphosphine)palladium(0) (85 mg,
0.074 mmol), 4b (417 mg, 1.46 mmol) and cesium carbonate (1.19 g,
3.65 mmol) following General Procedure 1. Purification was accom-
plished by FCC using 4:1 hexanes/ethyl acetate to give 140 mg
(0.441 mmol, 60 %) of 11h as a yellow solid. Mp 174 °C. 1H NMR
(400 MHz, CD2Cl2) : δ = 9.55 (s, 1H, NH), 7.56–7.52 (m, 3H,
7′-H, 2′′′-H, 6′′′-H), 7.42 (ddd, J = 8.3 Hz, 6.9 Hz, 1.1 Hz, 1H, 6′-H),
7.39–7.35 (m, 1H, 4′-H), 7.35–7.31 (m, 1H, 4′′′-H), 7.30–7.25 (m, 2H,
3′′′-H, 5′′′-H), 7.14 (ddd, J = 8.1 Hz, 6.9 Hz, 1.0 Hz, 1H, 5′-H), 2.16 (s,
3H, 2-H), 2.12 (s, 3H, 3′′-CH3) ppm. 13C NMR (101 MHz, CD2Cl2): δ =
190.6 (C-1), 166.1 (C-5′′), 161.7 (C-3′′), 136.9 (C-7a′), 133.8 (C-2′),
130.6 (C-4′′′), 129.5 (C-3′′′, C-5′′′), 128.8 (C-3a′), 128.2 (C-1′′′), 127.5
(C-6′), 126.5 (C-2′′′, C-6′′′), 122.1 (C-5′), 122.0 (C-4′), 112.9 (C-7′),
111.1 (C-3′), 108.4 (C-4′′), 27.9 (C-2), 10.7 (3′′-CH3) ppm. IR (KBr): ν˜ =
3314, 3059, 2926, 1645, 1532, 1482, 1405, 1333, 1251, 1131, 944,
773, 693 cm–1. HRMS (ESI): m/z = 317.1584 [M + H]+ (calcd for
C20H17N2O2+: 317.1285). HPLC purity (method c): 97 % (λ = 210 nm),
> 99 % (λ = 254 nm).
1-[5-Methoxy-3-(3-methyl-5-phenylisoxazol-4-yl)-1H-indol-2-
yl]ethan-1-one (11i): Prepared from 2-acyl-3-bromoindole 9d
(152 mg, 0.567 mmol), tetrakis(triphenylphosphine)palladium(0)
(71 mg, 0.061 mmol), 4b (323 mg, 1.13 mmol) and cesium carb-
onate (924 g, 2.83 mmol) following General Procedure 1. Purifica-
tion was accomplished by FCC using 4:1 hexanes/ethyl acetate to
give 120 mg (0.346 mmol, 61 %) of 11i as a pale yellow solid. Mp
164 °C. 1H NMR (500 MHz, CD2Cl2): δ = 9.45 (s, 1H, NH), 7.57–7.54
(m, 2H, 2′′′-H, 6′′′-H), 7.43 (dd, J = 9.0 Hz, 0.5 Hz, 1H, 7′-H), 7.36–
7.32 (m, 1H, 4′′′-H), 7.31–7.26 (m, 2H, 3′′′-H, 5′′′-H), 7.07 (dd, J =
9.0 Hz, 2.4 Hz, 1H, 6′-H), 6.69 (d, J = 2.4 Hz, 1H, 4′-H), 3.69 (s, 3H,
OCH3), 2.14 (s, 3H, 3 ′′-CH3), 2.13 (s, 3H, 2-H) ppm. 13C NMR
(126 MHz, CD2Cl2): δ = 190.3 (C-1), 166.1 (C-5′′), 161.8 (C-3′′), 156.0
(C-5′), 134.2 (C-2′), 132.2 (C-7a′), 130.6 (C-4′′′), 129.5 (C-3′′′, C-5′′′),
129.3 (C-3a′), 128.3 (C-1′′′), 126.5 (C-2′′′, C-6′′′), 119.4 (C-6′), 114.0
(C-7′), 110.6 (C-3′), 108.6 (C-4′′), 101.3 (C-4′), 56.1 (OCH3), 27.8 (C-2),
10.8 (3′′-CH3) ppm. IR (KBr): ν˜ = 3311, 3062, 2928, 1643, 1496, 1459,
1275, 1250, 1218. 1162, 1033, 770, 689 cm–1. HRMS (ESI): m/z =
347.1390 [M + H]+ (calcd for C21H19N2O3+: 347.1390). HPLC purity
(method b): 99 % (λ = 210 nm), 99 % (λ = 254 nm).
1-[3-(3-Propyl-5-(pyridin-2-yl)isoxazol-4-yl)-1H-indol-2-yl]-
ethan-1-one (11j): Prepared from 2-acyl-3-bromoindole 1a
(224 mg, 0.941 mmol), tetrakis(triphenylphosphine)palladium(0)
(108 mg, 0.0935 mmol), 4c (589 mg, 1.87 mmol) and cesium carb-
onate (1.56 g, 4.79 mmol) following General Procedure 1. Purifica-
tion was accomplished by FCC using 2:1 hexanes/ethyl acetate to
give 115 mg (0.333 mmol, 35 %) of 11j as a yellow solid. Mp 163 °C.
1H NMR (500 MHz, CDCl3): δ = 9.40 (s, 1H, NH), 8.51 (ddd, J = 4.8 Hz,
1.7 Hz, 0.9 Hz, 1H, 3′′′-H), 7.62–7.58 (m, 1H, 5′′′-H), 7.53–7.47 (m, 2H,
7′-H, 6′′′-H), 7.39 (ddd, J = 8.3 Hz, 6.9 Hz, 1.1 Hz, 1H, 6′-H), 7.35–
7.32 (m, 1H, 4′-H), 7.20 (ddd, J = 7.5 Hz, 4.8 Hz, 1.2 Hz, 1H, 4′′′-H),
7.12 (ddd, J = 8.0 Hz, 6.9 Hz, 0.9 Hz, 1H, 5′-H), 2.57–2.50 (m, 2H,
1′′′′-H), 2.23 (s, 3H, 2-H), 1.60–1.52 (m, 2H, 2′′′′-H), 0.86 (t, J = 7.4 Hz,
3H, 3′′′′-H) ppm. 13C NMR (126 MHz, CDCl3): δ = 190.9 (C-1), 164.8
(C-3′′, C-5′′), 150.3 (C-3′′′), 147.0 (C-1′′′), 136.8 (C-5′′′), 136.1 (C-7a′),
133.7 (C-2′), 128.5 (C-3a′), 126.9 (C-6′), 124.3 (C-4′′′), 121.9 (C-6′′′),
121.8 (C-4′), 121.5 (C-5′), 112.4 (C-7′), 110.9 (C-3′), 110.1 (C-4′′), 27.8
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(C-2), 27.5 (C-1′′′′), 21.1 (C-2′′′′), 13.9 (C-3′′′′) ppm. IR (KBr): ν˜ = 3313,
3055, 2960, 2870, 1645, 1534, 1473, 1418, 1331, 1250, 1092, 948,
743 cm–1. HRMS (ESI ) : m/z = 344.1409 [M – H]– (calcd for
C21H18N3O2–: 344.1405). HPLC purity (method c): 99 % (λ = 210 nm),
99 % (λ = 254 nm).
1-[5-Methoxy-3-(3-propyl-5-(pyridin-2-yl)isoxazol-4-yl)-1H-
indol-2-yl]ethan-1-one (11k): Prepared from 2-acyl-3-bromoindole
9d (131 mg, 0.489 mmol), tetrakis(triphenylphosphine)palladium(0)
(59 mg, 0.051 mmol), 4c (325 mg, 1.03 mmol) and cesium carbonate
(810 mg, 2.49 mmol) following General Procedure 1. Purification
was accomplished by FCC using 3:1 hexanes/ethyl acetate to give
88 mg (0.23 mmol, 47 %) of 11k as a yellow solid. Mp 144 °C. 1H
NMR (500 MHz, CDCl3): δ = 9.53 (s, 1H, NH), 8.55 (ddd, J = 4.8 Hz,
1.7 Hz, 0.9 Hz, 1H, 3′′′-H), 7.61–7.57 (m, 1H, 5′′′-H), 7.49–7.47 (m, 1H,
6′′′-H), 7.38 (d, J = 9.0 Hz, 1H, 7′-H), 7.21 (ddd, J = 7.6 Hz, 4.8 Hz,
1.1 Hz, 1H, 4′′′-H), 7.05 (dd, J = 9.0 Hz, 2.4 Hz, 1H, 6′-H), 6.63 (d, J =
2.4 Hz, 1H, 4′-H), 3.71 (s, 3H, OCH3), 2.57–2.52 (m, 2H, 1′′′′-H), 2.20
(s, 3H, 2-H), 1.60–1.52 (m, 2H, 2′′′′-H), 0.87 (t, J = 7.4 Hz, 3H, 3′′′′-H)
ppm. 13C NMR (126 MHz, CDCl3): δ = 190.7 (C-1), 164.9 (C-3′′), 164.7
(C-5′′), 155.4 (C-5′), 150.4 (C-3′′′), 146.9 (C-1′′′), 136.9 (C-5′′′), 134.0
(C-2′), 131.6 (C-7a′), 128.8 (C-3a′), 124.3 (C-4′′′), 121.9 (C-6′′′), 119.0
(C-6′), 113.6 (C-7′), 110.3 (C-3′, C-4′′), 100.9 (C-4′), 55.8 (OCH3), 27.7
(C-2), 27.5 (C-1′′′′), 21.1 (C-2′′′′), 13.9 (C-3′′′′) ppm. IR (KBr): ν˜ = 3314,
3049, 2958, 2929, 1639, 1529, 1473, 1417, 1251, 1218, 1163, 1034,
970, 784 cm–1. HRMS (ESI): m/z = 376.1656 [M + H]+ (calcd for
C22H22N3O3+: 376.1656). HPLC purity (method c): 99 % (λ = 210 nm),
> 99 % (λ = 254 nm).
1-(1-Butyl-3-methyl-9H-pyrido[3,4-b]indol-4-yl)ethan-1-one
(12a): Prepared from 11a (45 mg, 0.15 mmol), palladium on carbon
(17 mg, 0.016 mmol) and cesium carbonate (147 mg, 0.451 mmol)
following General Procedure 2. Purification was accomplished by
FCC using 2:1 hexanes/ethyl acetate to give 37 mg (0.13 mmol,
87 %) of 12a as a pale yellow solid. Mp 159 °C. 1H NMR (400 MHz,
CDCl3): δ = 8.62 (s, 1H, NH), 7.85 (d, J = 8.0 Hz, 1H, 5′-H), 7.53–7.45
(m, 2H, 7′-H, 8′-H), 7.21 (ddd, J = 8.1 Hz, 6.6 Hz, 1.6 Hz, 1H, 6′-H),
3.09–3.03 (m, 2H, 1′′), 2.76 (s, 3H, 2-H), 2.65 (s, 3H, 3′-CH3), 1.87–
1.77 (m, 2H, 2′′-H), 1.49 –1.37 (m, 2H, 3′′-H), 0.92 (t, J = 7.4 Hz, 3H,
4′′-H) ppm. 13C NMR (101 MHz, CDCl3): δ = 206.5 (C-1), 146.2
(C-1′), 141.3 (C-3′), 140.7 (C-8a′), 132.5 (C-9a′), 128.5 (C-7′), 127.9
(C-4′), 124.8 (C-4a′), 122.9 (C-5′), 120.5 (C-6′), 120.4 (C-4b′), 111.8
(C-8′), 34.5 (C-1′′), 32.4 (C-2), 31.3 (C-2′′), 23.1 (C-3′′), 21.9 (3′-CH3),
14.1 (C-4′′) ppm. IR (KBr): ν˜ = 3383, 3192, 3064, 2954, 2858, 1700,
1620, 1502, 1456, 1402, 1327, 1179, 748 cm–1. HRMS (EI): m/z =
280.1575 [M] (calcd for C18H20N2O: 280.1576). HPLC purity (method
c): > 99 % (λ = 210 nm), > 99 % (λ = 254 nm).
1-(3-Methyl-1-phenyl-9H-pyrido[3,4-b]indol-4-yl)ethan-1-one
(12b): Prepared from 11b (58 mg, 0.18 mmol), palladium on carbon
(28 mg, 0.026 mmol) and cesium carbonate (271 mg, 0.831 mmol)
following General Procedure 2. Purification was accomplished by
FCC using 3:1 hexanes/ethyl acetate to give 33 mg (0.11 mmol,
61 %) of 12b as a pale yellow solid. Mp 200 °C. 1H NMR (500 MHz,
CD2Cl2): δ = 8.80 (s, 1H, NH), 7.95–7.91 (m, 2H, 2′′-H, 6′′-H), 7.87 (dd,
J = 8.1 Hz, 0.9 Hz, 1H, 5′-H), 7.59–7.51 (m, 4H, 7′-H, 8′-H, 3′′-H,
5′′-H), 7.25 (ddd, J = 8.1 Hz, 6.5 Hz, 1.7 Hz, 1H, 6′-H), 2.78 (s, 3H, 2-
H), 2.69 (s, 3H, 3′-CH3) ppm. 13C NMR (126 MHz, CD2Cl2): δ = 206.3
(C-1), 143.0 (C-1′), 142.4 (C-3′), 141.5 (C-8a′), 138.7 (C-1′′), 132.4
(C-9a′), 129.6 (C-3′′, C-5′′), 129.5 (C-4′′), 129.1 (C-4′, C-7′), 128.7 (C-
2′′, C-6′′), 126.2 (C-4a′), 123.2 (C-5′), 120.9 (C-6′), 120.6 (C-4b′), 112.3
(C-8′), 32.5 (C-2), 22.2 (3′-CH3) ppm. IR (KBr): ν˜ = 3299, 3060, 2923,
1687, 1620, 1561, 1495, 1396, 1320, 1232, 1087, 742, 702 cm–1.
HRMS (EI): m/z = 300.1265 [M] (calcd for C20H16N2O: 300.1263).
HPLC purity (method c): 99 % (λ = 210 nm), > 99 % (λ = 254 nm).
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1-(3-Methyl-1-phenyl-9H-pyrido[3,4-b]indol-4-yl)ethan-1-one
(12c): Prepared from 11c (62 mg, 0.19 mmol), palladium on carbon
(21 mg, 0.020 mmol) and cesium carbonate (283 mg, 0.869 mmol)
following General Procedure 2. Purification was accomplished by
FCC using 4:1 hexanes/acetone to give 31 mg (0.10 mmol, 53 %) of
12b as a yellow solid. Mp 174 °C. 1H NMR (400 MHz, (CD3)2SO): δ =
11.59 (s, 1H, NH), 8.11 (dd, J = 3.7 Hz, 1.0 Hz, 1H, 5′′-H), 7.78–7.72
(m; 3H, 5′-H, 8′-H, 3′′-H), 7.59 (ddd, J = 8.2 Hz, 7.1 Hz, 1.1 Hz, 1H,
7′-H), 7.35 (dd, J = 5.1 Hz, 3.7 Hz, 1H, 4′′-H), 7.25 (ddd, J = 8.1 Hz,
7.1 Hz, 1.0 Hz, 1H, 6′-H), 2.76 (s, 3H, 2-H), 2.57 (s, 3H, 3′-CH3) ppm.
13C NMR (101 MHz, (CD3)2SO): δ = 205.6 (C-1), 142.7 (C-1′), 141.8 (C-
8a′), 140.0 (C-3′), 136.0 (C-1′′), 129.3 (C-9a′), 128.6 (C-7′, C-3′′), 128.5
(C-4′′), 128.2 (C-4′), 126.3 (C-5′′), 125.5 (C-4a′), 122.0 (C-5′), 120.2 (C-
6′), 118.7 (C-4b′), 112.9 (C-8′), 32.0 (C-2), 21.4 (3′-CH3) ppm. IR (KBr):
ν˜ = 3330, 3067, 2920, 1685, 1559, 1433, 1400, 1352, 1234, 1146,
741, 702 cm–1. HRMS (ESI): m/z = 305.0753 [M – H]– (calcd for
C18H13N2OS–: 305.0754). HPLC purity (method b): 95 % (λ = 210 nm),
> 99 % (λ = 254 nm).
1-(6-Methoxy-1,3-dimethyl-9H-pyrido[3,4-b]indol-4-yl)ethan-1-
one (12d): Prepared from 11d (52 mg, 0.18 mmol), palladium on
carbon (20 mg, 0.019 mmol) and cesium carbonate (207 mg,
0.635 mmol) following General Procedure 2. Purification was accom-
plished by FCC using 1:3 hexanes/ethyl acetate to give 38 mg
(0.14 mmol, 78 %) of 12d as a yellow solid. Mp 125 °C. 1H NMR
(400 MHz, CD2Cl2): δ = 8.58 (s, 1H, NH), 7.43 (dd, J = 8.9 Hz, 0.5 Hz,
1H, 8′-H), 7.25 (d, J = 2.5 Hz, 1H, 5′-H), 7.17 (dd, J = 8.9 Hz, 2.5 Hz,
1H, 7′-H), 3.85 (s, 3H, OCH3), 2.74 (s, 3H, 1′-CH3), 2.72 (s, 3H, 2-H),
2.59 (s, 3H, 3′-CH3) ppm. 13C NMR (101 MHz, CD2Cl2): δ = 206.4 (C-
1), 154.7 (C-6′), 142.7 (C-1′), 141.2 (C-3′), 136.2 (C-8a′), 134.1 (C-9a′),
128.2 (C-4′), 124.4 (C-4a′), 121.1 (C-4b′), 118.8 (C-7′), 113.1 (C-8′),
105.2 (C-5′), 56.4 (OCH3), 32.6 (C-2), 22.1 (3′-CH3), 20.6 (1′-CH3) ppm.
IR (KBr): ν˜ = 3440, 3155, 2955, 1700, 1686, 1582, 1496, 1309, 1221,
1034, 815, 778 cm–1. HRMS (EI): m/z = 268.1214 [M] (calcd for
C16H16N2O2: 268.1212). HPLC purity (method c): 99 % (λ = 210 nm),
99 % (λ = 254 nm).
1-(1-Butyl-6-methoxy-3-methyl-9H-pyrido[3,4-b]indol-4-yl)-
ethan-1-one (12e): Prepared from 11e (59 mg, 0.18 mmol), palla-
dium on carbon (20 mg, 0.019 mmol) and cesium carbonate
(144 mg, 0.442 mmol) following General Procedure 2. Purification
was accomplished by FCC using 2:1 hexanes/ethyl acetate to give
51 mg (0.16 mmol, 89 %) of 12e as a yellow solid. Mp 102 °C. 1H
NMR (400 MHz, CD2Cl2): δ = 8.87 (s, 1H, NH), 7.41 (d, J = 8.9 Hz, 1H,
8′-H), 7.26 (d, J = 2.5 Hz, 1H, 5′-H), 7.16 (dd, J = 8.9 Hz, 2.5 Hz, 1H,
7′-H), 3.85 (s, 3H, OCH3), 3.05–2.98 (m, 2H, 1′′-H), 2.74 (s, 3H, 2-H),
2.60 (s, 3H, 3′-CH3), 1.85–1.75 (m, 2H, 2′′-H), 1.45–1.33 (m, 2H,
3′′-H), 0.90 (t, J = 7.4 Hz, 3H, 4′′-H) ppm. 13C NMR (101 MHz, CD2Cl2):
δ = 206.6 (C-1), 154.6 (C-6′), 146.9 (C-1′), 141.1 (C-3′), 136.2 (C-8a′),
133.7 (C-9a′), 128.1 (C-4′), 124.7 (C-4a′), 121.1 (C-4b′), 118.7 (C-7′),
113.1 (C-8′), 105.1 (C-5′), 56.4 (OCH3), 34.6 (C-1′′), 32.7 (C-2), 31.4
(C-2′′), 23.4 (C-3′′), 22.1 (3′-CH3), 14.3 (C-4′′) ppm. IR (KBr): ν˜ = 3635,
3194, 2956, 2856, 1701, 1580, 1496, 1438, 1354, 1311, 1223, 1033,
778 cm–1. HRMS (EI): m/z = 310.1678 [M] (calcd for C19H22N2O2:
310.1681). HPLC purity (method c): 96 % (λ = 210 nm), 96 % (λ =
254 nm).
1-(6-Methoxy-3-methyl-1-phenyl-9H-pyrido[3,4-b]indol-4-yl)-
ethan-1-one (12f): Prepared from 11f (63 mg, 0.18 mmol), palla-
dium on carbon (20 mg, 0.019 mmol) and cesium carbonate
(213 mg, 0.654 mmol) following General Procedure 2. Purification
was accomplished by FCC using 4:1 hexanes/ethyl acetate to give
28 mg (0.085 mmol, 47 %) of 12f as a yellow solid. Mp 115 °C. 1H
NMR (400 MHz, CDCl3): δ = 8.40 (s, 1H, NH), 7.94–7.90 (m, 2H,
2′′-H, 6′′-H), 7.60–7.55 (m, 2H, 3′′-H, 5′′-H), 7.51–7.46 (m, 1H, 4′′-H),
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7.39 (d, J = 8.9 Hz, 1H, 8′-H), 7.31 (d, J = 2.4 Hz, 1H, 5′-H), 7.19 (dd,
J = 8.9 Hz, 2.5 Hz, 1H, 7′-H), 3.88 (s, 3H, OCH3), 2.80 (s, 3H, 2-H), 2.73
(s, 3H, 3′-CH3) ppm. 13C NMR (101 MHz, CDCl3): δ = 206.2 (C-1),
154.4 (C-6′), 143.1 (C-1′), 141.8 (C-3′), 138.2 (C-1′′), 136.0 (C-8a′),
132.7 (C-9a′), 129.4 (C-3′′, C-5′′), 129.2 (C-4′′), 128.6 (C-4′), 128.3
(C-2′′, C-6′′), 125.7 (C-4a′), 120.6 (C-4b′), 118.8 (C-7′), 112.6 (C-8′),
104.9 (C-5′), 56.2 (OCH3), 32.4 (C-2), 22.1 (3′-CH3) ppm. IR (KBr): ν˜ =
3372, 3057, 2925, 2831, 1695, 1571, 1490, 1280, 1220, 1143, 1031,
766, 694 cm–1. HRMS (EI): m/z = 330.1340 [M] (calcd for C21H18N2O2:
330.1368). HPLC purity (method c): > 99 % (λ = 210 nm), > 99 %
(λ = 254 nm).
1-(6-Methoxy-3-methyl-1-(thiophen-2-yl)-9H-pyrido[3,4-b]ind-
ol-4-yl)ethan-1-one (12g): Prepared from 11g (64 mg, 0.18 mmol),
palladium on carbon (19 mg, 0.018 mmol) and cesium carbonate
(207 mg, 0.635 mmol) following General Procedure 2. Purification
was accomplished by FCC using 4:1 hexanes/acetone to give 41 mg
(0.12 mmol, 67 %) of 12g as a yellow solid. Mp 170 °C. 1H NMR
(400 MHz, CD2Cl2): δ = 8.66 (s, 1H, NH), 7.74 (dd, J = 3.7 Hz, 1.1 Hz,
1H, 3′′-H), 7.51 (dd, J = 5.1 Hz, 1.0 Hz, 1H, 5′′-H), 7.46 (dd, J = 8.8 Hz,
0.5 Hz, 1H, 8′-H), 7.24–7.21 (m, 2H, 5′-H, 4′′-H), 7.17 (dd, J = 8.9 Hz,
2.5 Hz, 1H, 7′-H), 3.84 (s, 3H, OCH3), 2.75 (s, 3H, 2-H), 2.62 (s, 3H,
3′-CH3) ppm. 13C NMR (101 MHz, CD2Cl2): δ = 206.2 (C-1), 155.0
(C-6′), 143.3 (C-1′), 142.0 (C-3′), 137.1 (C-1′′), 136.6 (C-8a′), 131.7
(C-9a′), 129.0 (C-4′), 128.6 (C-4′′), 128.1 (C-5′′), 126.7 (C-4a′), 125.8
(C-3′′), 120.9 (C-4b′), 119.0 (C-7′), 113.3 (C-8′), 105.1 (C-5′), 56.3
(OCH3), 32.6 (C-2), 22.1 (3′-CH3) ppm. IR (KBr): ν˜ = 3413, 3303, 3091,
2958, 2831, 1686, 1559, 1487, 1353, 1279, 1145, 1033, 847, 721 cm–
1. HRMS (ESI): m/z = 335.0859 [M – H]– (calcd for C19H15N2O2S–:
335.0860). HPLC purity: 98 % (λ = 210 nm), > 99 % (λ = 254 nm).
(1,3-Dimethyl-9H-pyrido[3,4-b]indol-4-yl)(phenyl)methan-1-one
(12h): Prepared from 11h (82 mg, 0.26 mmol), palladium on carbon
(28 mg, 0.026 mmol) and cesium carbonate (284 mg, 0.872 mmol)
following General Procedure 2. Purification was accomplished by
FCC using 1:3 hexanes/ethyl acetate to give 55 mg (0.18 mmol,
69 %) of 12h as a yellow solid. Mp 215 °C. 1H NMR (400 MHz, CDCl3):
δ = 8.75 (s, 1H, NH), 7.97–7.92 (m, 1H, 2′-H, 6′-H), 7.63–7.57 (m, 1H,
4′-H), 7.50–7.39 (m, 5H, 5-H, 7-H, 8-H, 3′-H, 5′-H), 7.00 (ddd, J =
8.1 Hz, 5.9 Hz, 2.3 Hz, 1H, 6-H), 2.82 (s, 3H, 1-CH3), 2.51 (s, 3H, 3-
CH3) ppm. 13C NMR (101 MHz, CDCl3): δ = 198.6 (C=O), 143.0 (C-3),
142.0 (C-1), 140.8 (C-8a), 137.1 (C-1′), 134.3 (C-4′), 132.8 (C-9a), 130.0
(C-2′, C-6′), 129.2 (C-3′, C-5′), 128.5 (C-7), 126.3 (C-4a), 125.4 (C-4),
123.4 (C-5), 120.6 (C-4b), 120.4 (C-6), 111.7 (C-8), 22.2 (3-CH3), 20.5
(1-CH3) ppm. IR (KBr): ν˜ = 3448, 3138, 3086, 2918, 1667, 1593, 1401,
1239, 1144 957, 866, 745 cm–1. HRMS (ESI): m/z = 299.1190 [M –
H]– (calcd for C20H15N2O–: 299.1190). HPLC purity (method c):
> 99 % (λ = 210 nm), > 99 % (λ = 254 nm).
(6-Methoxy-1,3-dimethyl-9H-pyrido[3,4-b]indol-4-yl)(phenyl)-
methan-1-one (12i): Prepared from 11i (60 mg, 0.17 mmol), palla-
dium on carbon (20 mg, 0.019 mmol) and cesium carbonate
(202 mg, 0.620 mmol) following General Procedure 2. Purification
was accomplished by FCC using 1:3 hexanes/ethyl acetate to give
49 mg (0.15 mmol, 88 %) of 12i as a yellow solid. Mp 207 °C. 1H
NMR (500 MHz, CD2Cl2): δ = 8.53 (s, 1H, NH), 7.95–7.90 (m, 1H, 2′-
H, 6′-H), 7.64–7.59 (m, 1H, 4′-H), 7.50–7.44 (m, 2H, 3′-H, 5′-H), 7.39
(d, J = 8.9 Hz, 1H, 8-H), 7.06 (dd, J = 8.9 Hz, 2.5 Hz, 1H, 7-H), 6.78
(d, J = 2.5 Hz, 1H, 5-H), 3.53 (OCH3), 2.80 (s, 3H, 1-CH3), 2.48 (s, 3H,
3-CH3) ppm. 13C NMR (126 MHz, CD2Cl2): δ = 198.7 (C=O), 154.4 (C-
6), 143.2 (C-3), 142.9 (C-1), 137.9 (C-1′), 136.1 (C-8a), 134.5 (C-4′),
133.9 (C-9a), 130.2 (C-2′, C-6′), 129.6 (C-3′, C-5′), 126.1 (C-4a), 125.5
(C-4), 121.2 (C-4b), 118.8 (C-7), 112.9 (C-8), 105.3 (C-5), 56.0 (OCH3),
22.3 (3-CH3), 20.7 (1-CH3) ppm. IR (KBr): ν˜ = 3448, 3114, 3034, 2924,
2853, 1664, 1578, 1491, 1305, 1220, 1026, 880, 684 cm–1. HRMS
Full Paper
doi.org/10.1002/ejoc.202000230
EurJOC
European Journal of Organic Chemistry
(ESI): m/z = 329.1295 [M – H]– (calcd for C21H17N2O2–: 329.1296).
HPLC purity (method c): > 99 % (λ = 210 nm), > 99 % (λ = 254 nm).
R,S-(1-Methyl-3-propyl-9H-pyrido[3,4-b]indol-4-yl)(pyridin-2-
yl)methanol (12j): Prepared from 11j (67 mg, 0.19 mmol), palla-
dium on carbon (21 mg, 0.020 mmol) and cesium carbonate
(195 mg, 0.598 mmol) following General Procedure 2. Purification
was accomplished by FCC using 1:9 hexanes/ethyl acetate and 5 %
triethylamine to give 55 mg (0.16 mmol, 84 %) of 12j as a yellow
solid. Mp 210 °C. 1H NMR (400 MHz, (CD3)2CO): δ = 10.49 (s, 1H,
NH), 8.58–8.54 (m, 1H, 3′′-H), 8.13 (d, J = 8.2 Hz, 1H, 5′-H), 7.70–7.64
(m, 1H, 5′′-H), 7.50 (d, J = 7.4 Hz, 1H, 8′-H), 7.36 (ddd, J = 8.2 Hz,
7.1 Hz, 1.1 Hz, 1H, 7′-H), 7.29 (d, J = 7.9 Hz, 1H, 6′′-H), 7.26–7.21 (m,
1H, 4′′-H), 7.00–6.95 (m, 1H, 6′-H), 6.78 (s, 1H, 1-H), 5.54 (s, 1H, OH),
2.99–2.92 (m, 2H, 1′′′-H), 2.76 (s, 3H, 1′-CH3), 1.80–1.55 (m, 2H, 2′′′-
H), 0.91 (t, J = 7.4 Hz, 3H, 3′′′-H) ppm. 13C NMR (101 MHz, (CD3)2CO):
δ = 163.0 (C-1′′), 150.2 (C-3′), 149.0 (C-3′′), 142.0 (C-8a′), 141.5
(C-1′), 137.5 (C-5′′), 134.7 (C-9a′), 128.0 (C-4a′), 127.7 (C-7′), 127.6
(C-4′), 126.8 (C-5′), 122.9 (C-4′′), 122.5 (C-4b′), 121.6 (C-6′′), 119.5 (C-
6′), 112.2 (C-8′), 71.9 (C-1), 38.6 (C-1′′′), 24.9 (C-2′′′), 20.6 (1′-CH3),
14.6 (C-3′′′) ppm. IR (KBr): ν˜ = 3444, 3145, 3091, 2957, 2871, 1619,
1470, 1332, 1125, 1057, 748 cm–1. HRMS (ESI): m/z = 330.1609 [M –
H]– (calcd for C21H20N3O–: 330.1612). HPLC purity (method c):
> 99 % (λ = 210 nm), > 99 % (λ = 254 nm).
R,S-(6-Methoxy-1-methyl-3-propyl-9H-pyrido[3,4-b]indol-4-yl)-
(pyridin-2-yl)methanol (12k): Prepared from 11k (73 mg,
0.19 mmol), palladium on carbon (24 mg, 0.023 mmol) and cesium
carbonate (219 mg, 0.672 mmol) following General Procedure 2.
Purification was accomplished by FCC using 1:9 hexanes/ethyl acet-
ate and 5 % triethylamine to give 46 mg (0.13 mmol, 68 %) of 12k
as a yellow solid. Mp 182 °C. 1H NMR (400 MHz, (CD3)2CO): δ =
10.30 (s, 1H, NH), 8.62–8.57 (m, 1H, 3′′-H), 7.69–7.64 (m, 1H, 5′′-H),
7.56 (d, J = 2.4 Hz, 5′-H), 7.36 (d, J = 8.8 Hz, 1H, 8′-H), 7.29–7.23 (m,
2H, 4′′-H, 6′′-H), 6.98 (dd, J = 8.8 Hz, 2.5 Hz, 1H, 7′-H), 6.66 (s, 1H, 1-
H), 5.57 (d, J = 1.8 Hz, 1H, OH), 3.66 (s, 3H, OCH3), 3.07–2.98 (m, 2H,
1′′′-H), 2.74 (s, 3H, 1′-CH3), 1.83–1.68 (m, 2H, 2′′′-H), 0.97 (t, J =
7.4 Hz, 3H, 3′′′-H) ppm. 13C NMR (101 MHz, (CD3)2CO): δ = 163.1 (C-
1′′), 154.0 (C-6′), 149.6 (C-3′), 149.1 (C-3′′), 141.9 (C-1′), 137.6 (C-5′′),
136.8 (C-8a′), 135.6 (C-9a′), 127.6 (C-4a′), 127.0 (C-4′), 123.0 (C-4′′),
122.5 (C-4b′), 121.6 (C-6′′), 118.1 (C-7′), 112.7 (C-8′), 108.8 (C-5′), 72.0
(C-1), 56.0 (OCH3), 38.7 (C-1′′′), 25.2 (C-2′′′), 20.6 (1′-CH3), 14.6
(C-3′′′) ppm. IR (KBr): ν˜ = 3432, 3128, 3082, 2953, 2827, 1594, 1579,
1495, 1434, 1302, 1222, 1038, 1001, 803 cm–1. HRMS (EI): m/z =
361.1784 [M·]+ (calcd for C22H23N3O2·+: 361.1785). HPLC purity
(method c): > 99 % (λ = 210 nm), > 99 % (λ = 254 nm).
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